PMC6560791_01
PSA trends in patients with PSA decline (a) and those with PSA progression (b) after the start of abiraterone acetate + dexamethasone. The percentage variation from baseline is given below the trends. A different scale is used to improve readability.
10.1177_1756287219854908-fig1.jpg
PMC6560791_01_10.1177_1756287219854908-fig1.jpg
fig1-1756287219854908
Figure 1, five patients after 6 weeks and five patients after 12 weeks had a biochemical response thus confirming the antitumour activity of dexamethasone. bPFS was similar to that in the SWITCH trial (4.77 months versus 5.3 months, median), despite our patients having a worse rPFS (7.2 months versus 11.8 months) and OS (14.1 months versus 20.9 months). From our limited data there seems to be a specific subset of patients that responded better and thus benefited more from a steroid switch; we found a moderate positive correlation between long time to castration resistance, median duration of abiraterone acetate + dexamethasone and bPFS (r = 0.66, 95% CI 0.09-0.90; p = 0.029), even though there was no statistically significant correlation between entity of response to abiraterone acetate + prednisone and duration of bPFS on abiraterone acetate + dexamethasone (r = 0.56, 95% CI 0.08-0.92; p = 0.074).